Nilotinib

Evidence Level: L5

Predicted Indications: 1

Nilotinib

Pharmacist Assessment Report

Nilotinib: From BCR-ABL1-Positive Chronic Myelogenous Leukemia to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Nilotinib is a tyrosine kinase inhibitor originally used to treat BCR-ABL1-positive chronic myelogenous leukemia. The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), but currently only 1 review article supports this direction and no registered clinical trials were found. The prediction is mechanistically plausible but remains at the research-question stage.

Quick Overview

Item	Content
Original Indication	Chronic myelogenous leukemia, BCR-ABL1 positive
Predicted New Indication	Dermatofibrosarcoma protuberans
TxGNN Prediction Score	0.9931
Evidence Level	L5 (the data compiled for this report rates it L4; only a general review exists, with no nilotinib-specific study, so model prediction is effectively the main support)
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for nilotinib is not available in the data compiled for this report. Based on general knowledge, nilotinib is a tyrosine kinase inhibitor that blocks BCR-ABL1, and it also inhibits PDGFR, KIT and DDR kinases.

DFSP is typically driven by the COL1A1-PDGFB fusion, which causes constitutive autocrine activation of PDGFRB. Because nilotinib can inhibit PDGFR, there is a plausible mechanistic link between its activity in leukemia (kinase inhibition) and the growth signal that drives DFSP. The very high TxGNN score (0.9931) is consistent with this biology.

An important caveat: the single supporting publication is a 2018 review of small-molecule PDGFR inhibitors in neoplastic disorders. It appears to centre on imatinib, the established PDGFR inhibitor for this disease, and is not nilotinib-specific clinical evidence. The mechanism described here is inferred from the drug class, not from the data provided.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29408302	2018	Review	Pharmacological Research	Review of small-molecule PDGFR inhibitors in neoplastic disorders, covering the PDGF family and PDGFR signalling; likely focused on imatinib rather than nilotinib

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
216456	Tasigna 150mg Capsule	Strip of 4 capsules	Not specified in available data
215851	Tasigna 200mg Capsule	Strip of 4 capsules	Not specified in available data

Both licences are held by Novartis India Ltd and are currently valid. Both are oral single-ingredient products.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions (the knowledge graph lists neutropenia, thrombocytopenia and anemia as contraindicated conditions, suggesting haematological risk)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC, liver function, electrolytes (potassium, magnesium), blood glucose, ECG for QT interval
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Contraindicated or high-caution conditions (from the knowledge graph, not label text):
- Cardiovascular: long QT syndrome (including familial), torsades de pointes, hypertension
- Liver, biliary and pancreatic: liver disease, gallbladder disease, hyperbilirubinemia (including Gilbert syndrome), pancreatitis
- Blood: thrombocytopenia, neutropenia, agranulocytosis, anemia
- Metabolic: hyperglycemia, diabetes mellitus, diabetic ketoacidosis, potassium deficiency, hypophosphatemia, hypercalcemia, nephrocalcinosis, phosphorus metabolism disorders
Drug Interactions: 637 interactions were identified in total. Major-level examples include:
- Dexamethasone
- Clarithromycin
- Picosulfuric acid
- Polyethylene glycol (3350 with electrolytes)
Moderate-level examples include acid-suppressing drugs (famotidine, ranitidine, rabeprazole, omeprazole, cimetidine), corticosteroids (hydrocortisone, triamcinolone, betamethasone, budesonide), pioglitazone, loperamide, bupropion, aprepitant, bisacodyl and saxagliptin.

Package insert warnings and contraindications were not available. Please refer to the package insert for authoritative safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The PDGFR-driven biology of DFSP gives a plausible mechanistic link and the TxGNN score is high. However, there are no registered clinical trials and no nilotinib-specific literature; the only supporting item is a general review that appears to focus on imatinib. The established PDGFR inhibitor for this disease already exists, and nilotinib’s safety profile includes significant QT, metabolic and haematological concerns.

To proceed, the following is needed:

Nilotinib-specific evidence in DFSP (case series, phase 2 data, or preclinical studies in COL1A1-PDGFB models)
Comparative rationale against imatinib, including imatinib-resistant or intolerant patients
Mechanism of action data (MOA) confirmed from a primary source
Package insert warnings and contraindications for the India-marketed Tasigna products, plus their approved indication text
A safety plan covering QT monitoring, and review of the major drug interactions listed above
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.